F5

Summary

Gene Symbol: F5
Description: coagulation factor V
Alias: Ac2-120, coagulation factor V, coagulation factor V (proaccelerin, labile factor)
Species: rat

Top Publications

  1. ncbi Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction
    Katharina Middendorf
    Medical Clinic I, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany
    Am Heart J 147:897-904. 2004
  2. ncbi Arterial thrombosis resulting in amputation in a child with poorly controlled type 1 diabetes and heterozygous Factor V Leiden mutation
    Michael J Haller
    Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL, USA
    Pediatr Diabetes 7:229-31. 2006
  3. ncbi Blood coagulation
    Lucy A Norris
    Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity College Centre for Health Sciences, St James s Hospital, 8, Dublin, Ireland
    Best Pract Res Clin Obstet Gynaecol 17:369-83. 2003
  4. pmc Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis
    Ines J Laudes
    Departments of Pathology and Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 160:1867-75. 2002
  5. ncbi Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency
    R van Wijk
    Department of Clinical Chemistry, University Medical Centre, Utrecht, The Netherlands
    Br J Haematol 114:871-4. 2001
  6. pmc The concentrations of EGFR, LRG1, ITIH4, and F5 in serum correlate with the number of colonic adenomas in ApcPirc/+ rats
    Melanie M Ivancic
    Department of Biochemistry, University of Wisconsin Madison, Madison, Wisconsin
    Cancer Prev Res (Phila) 7:1160-9. 2014
  7. ncbi Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury
    Z Xu
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 49109 0644, USA
    Thromb Haemost 85:441-4. 2001
  8. ncbi Spontaneous thrombosis in mice carrying the factor V Leiden mutation
    J Cui
    Division of Medical Genetics, Department of Human Genetics, University of Michigan Medical Center, Ann Arbor MI, USA
    Blood 96:4222-6. 2000
  9. pmc Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
    Mari Tinholt
    Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway
    BMC Cancer 14:845. 2014
  10. ncbi Incidence of factor V Leiden in patients with acute myocardial infarction
    M S Gowda
    University of MissouriKansas City, Mid America Heart Institute and Department of Pathology, St Lukes Hospital, Kansas City, Missouri, USA
    J Thromb Thrombolysis 9:43-5. 2000

Scientific Experts

  • Virginie Siguret
  • Nina Iversen
  • L A Norris
  • D Kalayci
  • Pasquale Capaccio
  • P Ludemann
  • D H Verity
  • K Gorur
  • Valeria Nagy
  • Beril Akman
  • Ozan Emiroglu
  • Michael J Haller
  • Chieh L Wong
  • Thomas L Benfield
  • Martin Weger
  • M G Engelmann
  • L Hefler
  • Klaus Juul
  • Stephanie A Smith
  • E Kerschen
  • Børge G Nordestgaard
  • Anne Tybjaerg-Hansen
  • Mari Tinholt
  • Melanie M Ivancic
  • Ning Liu
  • Rachel Kaiser
  • Sarra Klai
  • Maren Weischer
  • Noriko Konishi
  • Gaurav Tripathi
  • Hiroki Saito
  • Pavanato Maria Amália
  • Takahiko Ono
  • Fumiaki Nogaki
  • Gabriella Cadoni
  • R L Goforth
  • Yakup Ekmekci
  • Giorgio Mello
  • Sophie Arsene
  • Elisabetta Castoldi
  • Katharina Middendorf
  • Stefano Duga
  • Mauro Silingardi
  • I Hernandez
  • H Weiler
  • James H Morrissey
  • M Maas
  • M Zogg
  • Richard J Travers
  • Oystein Garred
  • Hans Kristian Moen Vollan
  • Anders Erik Dahm
  • Benedicte Alexandra Lie
  • Per Morten Sandset
  • Anne Lise Børresen-Dale
  • Kristine Kleivi Sahlberg
  • Vessela Kristensen
  • Michael R Sussman
  • Amy A Irving
  • Ida Bukholm
  • Anne Flem Jacobsen
  • Ines J Laudes
  • Grethe Skretting
  • William F Dove
  • Kelli G Jonakin
  • Ellen Schlichting
  • Marte Kathrine Viken
  • Rolf Karesen
  • Robert P Kimberly
  • Gerald McGwin
  • Graciela S Alarcon
  • Jeffrey C Edberg
  • Anouer Ghachem
  • Kimberly E Taylor
  • Luis M Vila
  • Najiba Fekih-Mrissa
  • Michelle A Petri
  • Ann B Begovich
  • Monica Chang
  • Anis Baffoun
  • Rosalind Ramsey-Goldman
  • D Coen
  • Elizabeth E Brown
  • Brahim Nciri
  • Z Xu
  • Joseph Catanese
  • Yonghong Li
  • Jalel Hmida
  • Nasreddine Gritli
  • John D Reveille

Detail Information

Publications52

  1. ncbi Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction
    Katharina Middendorf
    Medical Clinic I, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany
    Am Heart J 147:897-904. 2004
    A point mutation in the gene encoding coagulation factor V is a cause of resistance against activated protein C. The presence of factor V Leiden is linked to 50% of congenital defects causing venous thrombosis...
  2. ncbi Arterial thrombosis resulting in amputation in a child with poorly controlled type 1 diabetes and heterozygous Factor V Leiden mutation
    Michael J Haller
    Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL, USA
    Pediatr Diabetes 7:229-31. 2006
    ..This report emphasizes the need to test for thrombophilic defects in children with thrombosis or with a family history of thrombosis. Good metabolic control is especially important in children with T1DM and known thrombophilic defects...
  3. ncbi Blood coagulation
    Lucy A Norris
    Coagulation Research Laboratory, Department of Obstetrics and Gynaecology, Trinity College Centre for Health Sciences, St James s Hospital, 8, Dublin, Ireland
    Best Pract Res Clin Obstet Gynaecol 17:369-83. 2003
    ..Both genetic and environmental factors can influence the activation of coagulation and may predispose affected individuals to thrombosis...
  4. pmc Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis
    Ines J Laudes
    Departments of Pathology and Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 160:1867-75. 2002
    ..Most of these parameters were reversed in CLP rats that had been treated with anti-C5a. Production of C5a during sepsis may directly or indirectly cause hemostatic defects that can be reduced by blockade of C5a...
  5. ncbi Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency
    R van Wijk
    Department of Clinical Chemistry, University Medical Centre, Utrecht, The Netherlands
    Br J Haematol 114:871-4. 2001
    ..predicting the synthesis of a truncated factor V (FV) molecule was identified in exon 13 of the human coagulation factor V gene in two unrelated Italian probands with undetectable plasma levels of FV antigen and activity...
  6. pmc The concentrations of EGFR, LRG1, ITIH4, and F5 in serum correlate with the number of colonic adenomas in ApcPirc/+ rats
    Melanie M Ivancic
    Department of Biochemistry, University of Wisconsin Madison, Madison, Wisconsin
    Cancer Prev Res (Phila) 7:1160-9. 2014
    ..EGFR, LRG1, ITIH4, and F5 displayed the most robust tumor-associated protein expression changes over time...
  7. ncbi Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury
    Z Xu
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 49109 0644, USA
    Thromb Haemost 85:441-4. 2001
    ..01 for both comparisons). These data demonstrate a strong relationship between aPC resistance and the pulmonary fibrosis that occurs following inflammatory lung injury...
  8. ncbi Spontaneous thrombosis in mice carrying the factor V Leiden mutation
    J Cui
    Division of Medical Genetics, Department of Human Genetics, University of Michigan Medical Center, Ann Arbor MI, USA
    Blood 96:4222-6. 2000
    A polymorphism in coagulation factor V, factor V Leiden (FVL), is the major known genetic risk factor for thrombosis in humans. Approximately 10% of mutation carriers experience clinically significant thrombosis in their lifetime...
  9. pmc Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
    Mari Tinholt
    Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway
    BMC Cancer 14:845. 2014
    ..To investigate the molecular mechanisms controlling cancer and hemostasis, we conducted a case-control study of genotypic and phenotypic variables of the tissue factor (TF) pathway of coagulation in breast cancer...
  10. ncbi Incidence of factor V Leiden in patients with acute myocardial infarction
    M S Gowda
    University of MissouriKansas City, Mid America Heart Institute and Department of Pathology, St Lukes Hospital, Kansas City, Missouri, USA
    J Thromb Thrombolysis 9:43-5. 2000
    The genetic defect of coagulation factor V known as factor V Leiden produces a resistance to degradation by activated protein C (APC) and increases the risk of venous thromboembolism...
  11. doi Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening
    Virginie Siguret
    UniversitéParis Descartes, Sorbonne Paris Cité, INSERM UMR S 1140, France Assistance Publique Hôpitaux de Paris, Service d Hematologie Biologique, Hopital Europeen Georges Pompidou, France
    J Gerontol A Biol Sci Med Sci 70:977-81. 2015
    ....
  12. pmc Survival advantage of heterozygous factor V Leiden carriers in murine sepsis
    E Kerschen
    Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, USA
    J Thromb Haemost 13:1073-80. 2015
    The high allelic frequency of the prothrombotic Leiden polymorphism in human blood coagulation factor V (FV) has been speculated to reflect positive selection during evolution...
  13. pmc How it all starts: Initiation of the clotting cascade
    Stephanie A Smith
    a Department of Biochemistry, University of Illinois at Urbana Champaign, Urbana, IL, USA
    Crit Rev Biochem Mol Biol 50:326-36. 2015
    ..This review focuses on how the initiation phase of the blood clotting cascade is regulated in both pathways, with a discussion of the contributions of these pathways to hemostasis versus thrombosis. ..
  14. ncbi Preferential consumption of coagulation factors I, V, and VIII in rat endotoxemia
    K Yamaguchi
    Department of Trauma and Critical Care, Yokosuka Kyosai Hospital, Kanagawa, Japan
    Shock 14:535-43. 2000
    ..The extrinsic coagulation pathway was dominantly activated, whereas the intrinsic coagulation pathway, including plasma kallikrein-kinin system, played less important role in the ETX-induced consumption coagulopathy in rat...
  15. ncbi Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients
    P Ludemann
    Department of Neurology, University of Münster Germany
    Stroke 29:2507-10. 1998
    ..To better define the relevance of the FVL mutation in conjunction with additional risk factors in CVT, we conducted the present case-control study...
  16. ncbi Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease
    A Gul
    Department of Internal Medicine, Istanbul Medical School, Turkey
    Br J Rheumatol 35:1178-80. 1996
    We investigated the prevalence of the coagulation factor V gene G1691A mutation in 64 patients with Behçet's disease (BD) and in 107 apparently healthy individuals. The mutation was present in the heterozygous state in 37...
  17. ncbi Tissue factor and factor v involvement in rat peritoneal fibrosis
    Hiroki Saito
    Division of Molecular Medicine, University of Shizuoka School of Pharmaceutical Sciences, Shizuoka, Japan
    Perit Dial Int 29:340-51. 2009
    ..The present study was conducted to clarify the contribution of factor Xa through tissue factor and factor V expression in peritoneal fibrosis...
  18. ncbi Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients
    Gabriella Cadoni
    Department of Otorhinolaryngology, Catholic University of the Sacred Heart, Rome, Italy
    Ann Otol Rhinol Laryngol 115:195-200. 2006
    ..We investigated the presence of congenital thrombophilic risk factors in a population of consecutive Italian patients affected by idiopathic sudden sensorineural hearing loss (SSNHL)...
  19. ncbi The role of factor V Leiden and prothrombin G20210A mutations in sudden sensorineural hearing loss
    Kemal Gorur
    Department of Otorhinolaryngology, University of Mersin School of Medicine, Mersin, Turkey
    Otol Neurotol 26:599-601. 2005
    ..To investigate the incidence of factor V Leiden and prothrombin G20210A in sudden sensorineural hearing loss patients...
  20. ncbi Quercetin prevents oxidative stress in cirrhotic rats
    Pavanato Maria Amália
    Department of Physiology and Pharmacology, Federal University of Santa Maria, Santa Maria, Brazil
    Dig Dis Sci 52:2616-21. 2007
    ..Quercetin (50 mg/kg/day) successfully attenuated these effects of CCl(4). We conclude that quercetin has beneficial effects on liver fibrosis in rats by enhancing antioxidant enzyme activity and decreasing the pro-oxidant effect...
  21. ncbi Genetic and acquired prothrombotic risk factors and sudden hearing loss
    Pasquale Capaccio
    Department of Otorhinolaryngological and Ophthalmological Sciences, Policlinico Foundation I R C C S, University of Milan, Milan, Italy
    Laryngoscope 117:547-51. 2007
    ..A number of inherited prothrombotic risk factors and their related genetic alterations have recently been correlated with vascular disorders...
  22. ncbi Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age
    Sophie Arsene
    Laboratoire d Hemostase, Hopital Trousseau, CHU de Tours, 37044 Tours Cedex 1, France
    Thromb Haemost 94:101-6. 2005
    ..027). In conclusion, this study suggests a role of FV Leiden in the occurrence of RVO in patients younger than 60 years who exhibit fewer acquired vascular risk factors than in older patients...
  23. ncbi Biosynthesis of factor V by normal adult rat hepatocytes
    M Mazzorana
    INSERM U 49, Hopital de Pontchaillou, Rennes, France
    Thromb Res 54:655-75. 1989
    The synthesis of coagulation factor V was investigated in isolated rat hepatocytes maintained in long-term primary culture. Two culture conditions were compared...
  24. ncbi Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis
    Mauro Silingardi
    Ospedale di Reggio Emilia, Regio Emilia, Italy
    Arthritis Rheum 51:177-83. 2004
    ..To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD)...
  25. ncbi Factor V Leiden mutation is associated with ocular involvement in Behçet disease
    D H Verity
    United Medical and Dental Schools of St Thomas and Guy s Hospitals, London, England
    Am J Ophthalmol 128:352-6. 1999
    ..We therefore investigated the prevalence of this mutation in patients with Behçet disease to determine its contribution to the presence and severity of ocular disease...
  26. ncbi Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion
    D Kalayci
    Department of Ophthalmology, Ankara Numune Hospital, Turkey
    Acta Ophthalmol Scand 77:622-4. 1999
    ..The role of factor V Leiden and prothrombin 20210 A mutations has been investigated in patients with central retinal vein occlusion (CRVO), hemispheric retinal vein occlusion (HRVO), and branch retinal vein occlusion (BRVO)...
  27. ncbi Activated protein C resistance in anterior ischaemic optic neuropathy
    Valeria Nagy
    Department of Ophthalmology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
    Acta Ophthalmol Scand 82:140-3. 2004
    Protein C is a major component of the natural anticoagulant pathway. Resistance of coagulation factor V (FV) to activated protein C (APC), mostly due to FV Leiden mutation, is the most common cause of inherited thrombophilia...
  28. ncbi The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients
    A B Irish
    Oxford Transplant Centre, The Churchill Hospital, Headington, United Kingdom
    Transplantation 64:604-7. 1997
    ..We investigated whether resistance to activated protein C due to a mutation in the factor V gene (FV Leiden/FV506Q) may predispose patients to thrombosis...
  29. doi Role of thrombotic risk factors in end-stage renal disease
    Gaurav Tripathi
    Department of Urology, CSSMU, Lucknow, Uttar Pradesh, India
    Clin Appl Thromb Hemost 16:132-40. 2010
    ..We have investigated the associations of these gene polymorphisms in patients with end-stage renal disease (ESRD)...
  30. pmc Thrombotic gene polymorphisms and postoperative outcome after coronary artery bypass graft surgery
    Ozan Emiroglu
    Department of Cardiovascular Surgery, Nicosia State Hospital, Nalbantoglu Lefkosa Devlet Hastanesi, Ortakoy, Nicosia, Cyprus
    J Cardiothorac Surg 6:120. 2011
    ....
  31. doi Thrombophilic disorders: a real threat to patients with end-stage renal disease on hemodialysis and at the time of renal transplantation
    Sarra Klai
    Unit of Molecular Biology, Department of Hematology, Military Hospital of Tunis, Tunis, Tunisia
    Blood Coagul Fibrinolysis 23:406-10. 2012
    ..These results will serve as a basis for anticoagulant prophylaxis aimed at preventing kidney rejection and renal allograft thrombosis...
  32. pmc Genetic risk factors for thrombosis in systemic lupus erythematosus
    Rachel Kaiser
    UCSF Division of Rheumatology, San Francisco, CA 94143, USA
    J Rheumatol 39:1603-10. 2012
    ..Thrombosis is a serious complication of systemic lupus erythematosus (SLE). We investigated whether genetic variants implicated in thrombosis pathways are associated with thrombosis among 2 ethnically diverse SLE cohorts...
  33. ncbi Thrombophilia and avascular necrosis of femoral head in kidney allograft recipients
    Yakup Ekmekci
    Department of Nephrology, Ankara University School of Medicine, Ibni Sina Hospital, 06100, Ankara, Turkey
    Nephrol Dial Transplant 21:3555-8. 2006
    ..We aimed to search for the relation of both prothrombin gene G20210A mutation and factor V G1691A (factor V Leiden) mutation with AVN among kidney transplant recipients...
  34. ncbi Renal vascular sclerosis is associated with inherited thrombophilias
    R L Goforth
    Department of Pathology, University of Iowa Hospitals and Clinics, Iowa, IA, USA
    Kidney Int 70:743-50. 2006
    ..001 compared to controls). These findings indicate that renal vascular lesions, in the absence of diabetes, hypertension, or smoking appears to be associated with inherited thrombophilias...
  35. ncbi Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list
    B Akman
    Department of Nephrology, Baskent University Hospital, Ankara, Turkey
    Transplant Proc 38:413-5. 2006
    ....
  36. ncbi Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study
    Giorgio Mello
    The Maternal Fetal Medicine High Risk Pregnancies Unit, University of Florence, Italy
    Hypertension 46:1270-4. 2005
    ..Thrombophilia also augments the risk of life-threatening maternal complications and adverse perinatal outcomes in preeclamptic patients...
  37. ncbi Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism
    D Coen
    Clinical Institute of Laboratory Diagnostics, Zagreb University Hospital Center, Zagreb, Croatia
    Croat Med J 42:488-92. 2001
    ..To determine the prevalences of factor V Leiden and the G20210A mutation in the prothrombin gene (PT20210A) and the frequency of their association in healthy subjects and in patients with venous thromboembolism (VTE)...
  38. ncbi Effect of dienogest on bleeding time, coagulation, fibrinolysis, and platelet aggregation in female rats
    H Nobukata
    Toxicology Laboratory, Mochida Pharmaceutical Co, Ltd, Fujieda, Shizuoka, Japan
    Toxicol Lett 104:93-101. 1999
    ..In comparison with MPA and danazol, dienogest may induce a relatively high incidence of bleeding in patients with endometriosis partially because of its minimal effect on hemostasis...
  39. ncbi Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study
    Lukas Hefler
    Department of Obstetrics and Gynecology, Vienna University Medical School, Vienna, Austria
    J Soc Gynecol Investig 11:42-4. 2004
    ..We determined whether gene polymorphisms associated with thrombophilia and vascular disease as etiologic factors were involved in the pathogenesis of pregnancy-associated complications...
  40. doi Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding
    Noriko Konishi
    Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Thromb Haemost 104:504-13. 2010
    ..These results suggest that the differential effects of the two agents on FV-mediated amplification of thrombin generation may underlie the observation of a wider therapeutic window for TAK-442 than for ximelagatran...
  41. doi Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension
    Chieh L Wong
    Haematology Department, Hammersmith Hospital, Imperial College Academic Health Science Centre, London, UK
    Blood Coagul Fibrinolysis 21:201-6. 2010
    ..The results indicate different pathophysiologies for CTEPH and non-CTEPH. The elevation of FVIII and increased incidence of FVL gene polymorphisms in the CTEPH group support a primary role of thrombosis in aetiology...
  42. doi Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population
    Maren Weischer
    Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark
    Atherosclerosis 208:480-3. 2010
    ....
  43. ncbi Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion
    M Weger
    Department of Ophthalmology Karl Franzens University Graz, Austria
    Eye (Lond) 17:731-4. 2003
    ..The purpose of the present study was therefore to investigate a possible association between factor V Leiden, prothrombin 20210A, and retinal artery occlusion...
  44. ncbi Coagulation in the mesangial area promotes ECM accumulation through factor V expression in MsPGN in rats
    Ning Liu
    Division of Nephrology, Department of Cardiovascular Medicine, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606 8507, Japan
    Am J Physiol Renal Physiol 287:F612-20. 2004
    ..The present results suggest that ECM components accumulation may progress in accordance with coagulation in the mesangial area through mesangial factor V expression and upregulated expression of TGF-beta and CTGF in MsPGN...
  45. ncbi Factor V Leiden and the risk for venous thromboembolism in the adult Danish population
    Klaus Juul
    Herlev University Hospital, Herlev, Denmark
    Ann Intern Med 140:330-7. 2004
    ..Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case-control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers...
  46. ncbi Hypereosinophilic syndrome associated with heterozygous factor V gene mutation: an unusual combination resulting in an acute coronary syndrome and recurrent cerebral stroke-a case report
    Markus G Engelmann
    Department of Cardiology, University Hospital Munich, Grosshadern, Munich, Germany
    Angiology 55:221-5. 2004
    ..In patients with hypereosinophilic syndrome and recurrent thromboembolic episodes, other thrombophilic diseases, including factor V mutations, should be considered, and long-term coagulation should be contemplated...
  47. ncbi Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study
    Thomas L Benfield
    Department of Infectious Diseases, Copenhagen University Hospital, Denmark
    J Infect Dis 192:1851-7. 2005
    The effect of the coagulation factor V Leiden mutation on infectious disease susceptibility and outcome is controversial.
  48. ncbi Factor V leiden homozygosity, dyspnea, and reduced pulmonary function
    Klaus Juul
    Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark
    Arch Intern Med 165:2032-6. 2005
    ..We tested the hypothesis that factor V Leiden homozygosity is associated with pulmonary symptoms and signs...
  49. ncbi Coagulation factor V
    Stefano Duga
    Department of Biology and Genetics for Medical Sciences, University of Milan, via Viotti 3 5, 20133 Milan, Italy
    Int J Biochem Cell Biol 36:1393-9. 2004
    ..This review focuses on the structure, function (procoagulant and anticoagulant), regulation (activation and inactivation) of FV as well as on the genetic defects associated with mutations in the FV gene...
  50. ncbi Factor V Leiden: a disorder of factor V anticoagulant function
    Elisabetta Castoldi
    Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6200 MD Maastricht, The Netherlands
    Curr Opin Hematol 11:176-81. 2004
    ..The present review covers the discovery, the physiological significance and the structural requirements of the APC-cofactor activity of FV...